Temporally controlled somatic mutagenesis in smooth muscle.
Ligand-dependent site-specific recombinases are powerful tools to engineer the mouse genome in specific somatic cell types at selected times during pre- and postnatal development. Current efforts are primarily directed towards increasing the efficiency of this recombination system in mice. We have generated transgenic mouse lines expressing a tamoxifen-activated Cre recombinase, CreER(T2), under the control of the smooth muscle-specific SM22 promoter. Both a randomly integrated transgene [SM-CreER(T2)(tg)] and a transgene that has been "knocked in" into the endogenous SM22 locus [SM-CreER(T2)(ki)] were expressed in smooth muscle-containing tissues. The level of CreER(T2) expression and tamoxifen-induced recombination was lower in SM-CreER(T2)(tg) mice compared with SM-CreER(T2)(ki) mice. Whereas no recombinase activity could be detected in vehicle-treated SM-CreER(T2)(ki) mice, administration of tamoxifen induced the excision of a loxP-flanked reporter transgene in up to 100% of smooth muscle cells. The recombined genome persisted for at least four months after tamoxifen treatment. SM-CreER(T2)(ki) transgenic mice should be useful to study the effects of various somatic mutations in smooth muscle.
Pubmed ID: 11020712 RIS Download
Animals | Gene Expression Regulation | Gene Targeting | Injections, Intraperitoneal | Integrases | Mice | Mice, Inbred C57BL | Mice, Transgenic | Microfilament Proteins | Muscle Proteins | Muscle, Smooth | Mutagenesis, Insertional | Organ Specificity | Promoter Regions, Genetic | RNA, Messenger | Receptors, Estrogen | Recombination, Genetic | Tamoxifen | Transgenes | Viral Proteins